Abstracts

714 – A Multimorbidity Model of HIV Disease Progression

Background Although life expectancy has improved and AIDS has declined, people with HIV (PWH) now develop more non-AIDS comorbidities. Health-related quality of life for PWH is now primarily influenced by those non-AIDS comorbidities rather than AIDS-defining conditions. We therefore propose a model of HIV disease progression which extends previous models via the inclusion of non-AIDS…

515 – Switch to DOR/ISL (100/0.25 mg) QD From Oral ART: Week 96 Update From an Open-Label Phase III Study

Background In an open-label, phase 3, randomized clinical study (MK-8591A-051; NCT05631093) in virologically suppressed adults with HIV-1, switching to the fixed combination of doravirine with islatravir (DOR/ISL 100/0.25 mg) once daily showed non-inferior efficacy to continuing oral antiretroviral therapy (ART) and was well tolerated at Week 48. We report on efficacy and safety results through…

537 – Four-Year Effectiveness of Doravirine-Based Antiretroviral Therapy in Treatment-Experienced PLWH

Background Doravirine (DOR), a non-nucleoside reverse transcriptase inhibitor, is approved for use in both antiretroviral therapy (ART)–naïve and –experienced people living with HIV (PLWH). We assessed the durability of virologic suppression in virologically suppressed, treatment‑experienced adults switched to DOR‑based regimens in routine care. Methods We performed a retrospective study in the large French DAT’AIDS cohort…

264 – Antilymphocyte Autoantibodies With Lytic Function Persist After ART in People With HIV

Background Self-reactive IgG antibodies (Abs), including those targeting the CD4 protein, have been previously identified in people with HIV (PWH), and are thought to mostly originate from a repertoire of cross-reactive anti-viral Ab. However, the kinetics, potential immunological function and clinical consequences of broad IgMs and IgGs anti-lymphocyte Abs (ALAbs) still need to be addressed.…

828 – Characterizing Immune Activation in HIV-Exposed but Uninfected Infants in the First Year of Life

Background Successful implementation of perinatal HIV prevention programs has greatly decreased the rate of vertical transmission. Most infants perinatally HIV-exposed are uninfected (HEU). Many health complications have been reported in HEU compared to HIV-unexposed (HUU) infants, including immune dysregulation and increased risk of infection, particularly before 12 months of age. Increased inflammation resulting from in…

1047 – Impact of Doxycycline Postexposure Prophylaxis on Antibiotic Use at a Boston Sexual Health Clinic

Background Doxycycline post-exposure prophylaxis (DPEP) is highly effective at preventing bacterial sexually transmitted infections (STIs) among men who have sex with men and trans women (MSMTW), but its impact on antibiotic prescribing is unclear. We assessed changes in patterns of antibiotic use among MSMTW at a Boston sexual health clinic that implemented DPEP in spring…